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Abstract
Liver transplantation represents the only curative option for patients with end-
stage liver disease, fulminant hepatitis and advanced hepatocellular carcinoma.
Even though major advances in transplantation in the last decades have achieved
excellent survival rates in the early post-transplantation period, long-term
survival is hampered by the lack of improvement in survival in the late post
transplantation period (over 5 years after transplantation). The main etiologies
for late mortality are malignancies and cardiovascular complications. The latter
are increasingly prevalent in liver transplant recipients due to the development
or worsening of metabolic syndrome and all its components (arterial
hypertension, dyslipidemia, obesity, renal injury, etc.). These comorbidities result
from a combination of pre-liver transplant features, immunosuppressive agent
side-effects, changes in metabolism and hemodynamics after liver transplantation
and the adoption of a sedentary lifestyle. In this review we describe the most
prevalent metabolic and cardiovascular complications present after liver
transplantation, as well as proposing management strategies.
Key words: Solid organ transplantation; Hypertension; New-onset diabetes after
transplantation; Obesity; Orthotopic liver transplantation; Post-transplantation metabolic
syndrome
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
WJG https://www.wjgnet.com May 14, 2020 Volume 26 Issue 182138
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
1
0
3
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Accepted: April 29, 2020
Article in press: April 29, 2020
Published online: May 14, 2020
P-Reviewer: Ciccone MM, Cimen
SG
S-Editor: Yang Y
L-Editor: A
E-Editor: Zhang YL
Core tip: Recently there has been an increasing interest in extra hepatic-related
complications after liver transplantation because they widely affect late morbidity and
mortality. Metabolic and cardiovascular diseases and de novo neoplasia are considered to
be among the main complications affecting long- and mid-term prognosis after liver
transplantation. In this review, we will assess the prevalence of metabolic and
cardiovascular complications after liver transplantation, their impact on post-transplant
morbidity and mortality, and the optimal medical management currently available.
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INTRODUCTION
Liver transplantation represents the only curative treatment option for end-stage liver
disease, chosen cases of acute liver failure and selected patients with hepatocellular
carcinoma, providing patients with a complete recovery of their liver function with
excellent survival and quality of life[1,2]. Advances in surgical techniques and post-
operative medical management have resulted in very good early post-transplant
survival rates in the last decades; however, late mortality has remained unchanged[3].
In Europe current reported survival rates are 83%, 71%, 61% and 51% at 1, 5, 10 and 15
years, respectively, with rates increasing up to 86% at 1-year and 74% at 5-year if the
period from 2010 to  2014 is  considered[4].  Similarly,  data  from the United States
indicates  85%, 68% and 50% 1-year,  5-year  and 10-year survival  rates  after  liver
transplantation, respectively, with significant differences according to the etiology of
the  underlying  liver  disease[5].  These  excellent  survival  rates  in  the  early  post-
transplantation period underline the importance of understanding the causes and risk
factors for late post-transplant mortality, in order to improve overall survival.
Late mortality is traditionally defined as death occurring 5 years or more after liver
transplantation[6]. Late mortality is predominantly not related to the liver graft (63%),
with high rates of cardiovascular causes and malignancies[7] . Although these findings
are in keeping with the main causes of mortality of the general population, patients
who underwent liver transplantation show higher risk for developing metabolic,
cardiovascular and neoplastic complications[8]. This is partially explained by the need
for chronic immunosuppressive drugs, the majority of which are associated with the
worsening or development of new-onset hypertension, dyslipidemia and diabetes[9,10].
However,  the  massive  adoption  of  the  Western-world  lifestyle  and  diet  have
dramatically  affected  metabolic  changes,  predisposing  and  increasing  the
development  of  cardiovascular  diseases[11].  Therefore,  the  unmet  goal  in  the
management of the post-liver transplantation follow-up is the prevention of these
long-term complications. In this review, we aim to review the prevalence of these late-
onset complications, their impact on post-transplant morbidity and mortality, and the
optimal management currently available.
METABOLIC SYNDROME
Metabolic syndrome is defined as a cluster of interrelated risk factors of metabolic
origin, involving insulin resistance and inflammation, which directly promote the
development of atherosclerotic cardiovascular disease and type 2 diabetes mellitus[12].
There are different definitions,  but most of  them consider hypertension,  obesity,
dyslipidemia, and diabetes mellitus as the main components of metabolic syndrome.
Its initial defining criteria, known as the World Health Organization criteria, have not
been consistently used because of the need to measure serum insulin and urinary
microalbumin to allow for the diagnosis, two expensive analyses[13].  Later on, the
Third Report of the National Cholesterol Education Program and the Adult Treatment
Panel III[14], proposed a more practical classification (initially described in 2001 and
successively revised in 2006[12]), that was widely accepted by the scientific community.
According to the National Cholesterol Education Program and the Adult Treatment
Panel III modified classification, metabolic syndrome is diagnosed when at least ≥ 3 of
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the following criteria are met: (1) Impaired glucose tolerance: Fasting plasma glucose
≥ 100 mg/dL (5.6 mmol/L); (2) Abdominal obesity: Waist circumference > 102 cm (40
in) in men, > 88 cm (35 in) in women; (3) Hypertriglyceridemia: ≥ 150 mg/dL (1.7
mmol/L) or drug treatment for high triglycerides; (4) Low levels of high-density
lipoproteins (HDL): < 40 mg/dL (1 mmol/L) in men, < 50 mg/dL (1.3 mmol/L) in
women or drug treatment for low HDL; and (5) High blood pressure: ≥ 130/85 mmHg
or drug treatment for hypertension.
Although originally these considerations on metabolic syndrome were described
for the general population, they are currently also adopted in transplanted patients.
Another attempt to classify this syndrome was made in 2005 by the International
Diabetes Federation criteria, establishing specific national cut-offs, in order to make
the classification uniform all over the world[15].
The prevalence of metabolic syndrome is higher in liver transplant recipients when
compared to the general population. Retrospective studies assessing the presence of
metabolic syndrome post liver transplantation detected this problem in 43%-58% of
recipients[16], compared to 30% of non-transplanted patients, with slight variations
according to different geographical areas[17]. A recent meta-analysis evaluated eight
original publications on metabolic syndrome after liver transplantation, underlining
some modifiable and non-modifiable risk factors[16]. Male gender, and components
present prior to transplantation such as high BMI[18], type 2 diabetes mellitus[19] and
hypertension were all related to the development of de novo metabolic syndrome. In
particular, patients suffering from diabetes mellitus before transplantation had a six-
fold higher risk for developing de novo metabolic syndrome[19]. When considering the
etiology  of  the  underlying  liver  disease  resulting  in  the  indication  for  liver
transplantation, patients affected by hepatitis C, cryptogenic cirrhosis [group that
possibly could include patients  with misdiagnosed non-alcoholic  steatohepatitis
(NASH)] and alcohol related cirrhosis were at higher risk of developing metabolic
syndrome after liver transplantation[16,19].
Although  the  data  are  not  completely  conclusive  on  the  effect  of  immu-
nosuppressive therapy on metabolic syndrome, the metabolic effects of these drugs
are well  established. Prolonged exposure to these drugs may increase the risk of
metabolic complications and/or affect the reversibility of comorbidities present before
transplantation. Corticosteroids, usually used in the early post-transplant phase, can
act directly on pancreas beta cells increasing insulin resistance, while calcineurin
inhibitors  can affect  the  development  both of  diabetes  mellitus  (particularly  for
tacrolimus) and of hypertension (mainly true for cyclosporine). Dyslipidemia is often
related to the use of mammalian target of rapamycin (mTOR) inhibitors, whereas the
use of anti-metabolites such as mycophenolate have fewer detrimental effects on
metabolic syndrome related comorbidities[20]. Considering that all these metabolic side
effects are related to immunosuppression, it is reasonable to think that these agents
may be the cause of metabolic syndrome. Nevertheless, there is no robust data to
support this relationship[21]. Minimizing the effective dose of immunosuppression and
supporting a healthy lifestyle are all measures recommended in order to prevent and
reduce the development of metabolic syndrome and its related comorbidities.
In the general population, metabolic syndrome is recognized as an independent
risk  factor  for  cardiovascular  morbidity  and mortality.  Regardless  of  the  single
components of metabolic syndrome, which represent themselves cardiovascular risk
factors,  metabolic  syndrome  is  a  cluster  of  metabolic  dysfunctions  that  play  a
multiplicative impact on cardiovascular prognosis[22]. In keeping with these findings,
metabolic  syndrome  has  been  extensively  studied  in  the  setting  of  liver
transplantation. In the aforementioned meta-analysis by Li et al[16], liver transplant
recipients patients with metabolic syndrome exhibited a higher rate of cardiovascular
events, but not poorer survival rates. Patients who are at high risk of developing
metabolic syndrome after liver transplantation should undergo regular surveillance in
order to achieve an earlier diagnosis and treatment. An early diagnosis of metabolic
syndrome  will  limit  possible  comorbidities,  thereby  reducing  the  risk  of
cardiovascular events. Additionally, patients who develop metabolic syndrome after
liver transplantation are at a higher risk of developing graft steatosis, leading to an
increase in the recurrence or in the development of de novo non-alcoholic fatty liver
disease  (NAFLD).  NAFLD de  novo  rates  range from 20% to  40%[23],  but  they can
increase to 78% when we consider patients transplanted for NASH[24].  This wide
variability  depends  on  the  methodology  used  for  liver  steatosis  diagnosis[25].
Nevertheless,  in  the  majority  of  cases,  the  recurrence of  NAFLD and NASH are
harmless, without an evolution towards cirrhosis[26]. Notably, patients with recurrent
NAFLD/NASH are more prone to develop cardiovascular  comorbidities,  type 2
diabetes  mellitus  and  suffer  from  increased  infection-related  morbidity  and
mortality[27]. Interestingly, recipient genetic predisposition might play a role in the
recurrence of NAFLD and NASH. The presence of the rs738409-G allele of the patatin-
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like phospholipase in liver transplant recipients represents an independent risk factor
for post-procedure development of obesity and steatosis[28].
DIABETES MELLITUS TYPE II
New-onset  diabetes  mellitus  type  II  after-liver  transplantation  is  increasingly
recognized  as  a  complication  of  solid  organ  transplantation.  It  is  defined  by  a
hemoglobin A1c (HbA1c) level ≥ 6.5% in the transplanted populations[29]. Data on the
prevalence  of  type  2  diabetes  in  patients  after  liver  transplantation  are  still
controversial. This is due to the heterogeneity of the criteria used for the diagnosis of
diabetes mellitus and to the variability in the follow-up time points in the different
studies. Nevertheless, the prevalence of type 2 diabetes mellitus ranges from 31% to
38% in post-liver transplantation patients, while the incidence of new onset type 2
diabetes ranges from 13% to 28% in the first three years following transplantation[29,30].
Diabetes mellitus has been demonstrated to have significant consequences in both the
early and late post-liver transplantation periods. When present, it was associated with
a higher 10-year mortality, compared to non-diabetic liver transplant patients[31].
Patients with diabetes mellitus are more prone to experience complications with an
increased risk of  cardiovascular events,  nephropathy,  infections and death[32].  In
addition, they experience a higher number of acute rejection episodes compared with
non-diabetic  patients,  with  higher  rates  of  graft  lost[33].  There  are  several  well-
established  risk  factors  associated  with  the  development  of  diabetes  after  liver
transplantation.  Male  gender [34],  ethnicity,  family  history [35],  hepatitis  C [36],
citomegalovirus infections[10], and immunosuppressive drugs significantly contribute
to the development of  new-onset  diabetes  mellitus  or  worsening of  pre-existing
diabetes.
Among the available immunosuppressive drugs, corticosteroids are undisputedly
known to increase the risk of new-onset diabetes in a length and dose-dependent
manner[37]. This diabetogenic effect represents one of the most worrisome side-effects
of glucocorticoids, justifying a strategy of rapid steroid withdrawal. Calcineurin-
inhibitors also have a known diabetogenic effect, by directly damaging pancreatic
islets cells. Although tacrolimus and cyclosporine share this mechanism of damage,
the risk of developing or worsening of diabetes is significantly higher with tacrolimus
than with cyclosporine (16.6% vs 9.8%, respectively), valid findings for all solid organ
recipients[38]. There is convincing evidence from the non-liver transplant population
that target glycemic levels significantly reduces morbidity and mortality in patients
with type 2 diabetes mellitus[39].  Although this approach has not been specifically
proven in the liver transplant population, and little information exists on the use of
anti-diabetic  drugs  in  this  subset  of  patients,  it  is  reasonable  to  assume  that
euglycemic status is  a goal  to achieve in post-liver transplantation management.
Expert consensus and guideline recommendations suggest screening transplanted
patients with basal glycaemia at weekly intervals during the first month following
transplantation and subsequently at 3, 6, and 12 mo, with additional annual screening
of diabetic complications[35,40]. The oral glucose test remains the best available test to
definitely assess new-onset diabetes mellitus[41]. It should be noted that diagnosis of
new-onset diabetes is not feasible in the first two months after liver transplantation[41],
since  in  the  immediate  post-transplant  period,  insulin  requirement  is  usually
increased,  being  the  safest  and  most  effective  therapy  to  treat  hyperglycemia.
However,  once  patients  have  returned  to  a  regular  eating  pattern  and  stable
immunosuppression, hyperglycemia may either disappear or, in the case of new onset
diabetes mellitus, persist. In concordance, use of HbA1c test is recommended 3 mo
post-liver transplantation due to possible peri-transplantation transfusions that render
the test invalid[40]. The goal for transplanted patients with established type 2 diabetes
mellitus should be an HbA1c level of less than 6.5%-7%[35]. An HbA1c level < 6.5% is
recommended for patients with a shorter disease duration, younger age and fewer
comorbidities.  In  older  patients  with  multiple  comorbidities  and  a  high  risk  of
hypoglycemia, an HbA1c of < 8.0% is considered a safer goal[42]. At present, there is
insufficient data to recommend a specific algorithm of anti-diabetic agents in post-
transplant diabetes mellitus, as studies addressing this specific population are lacking.
However, if current guidelines for the treatment of type 2 diabetes in the general
population  are  extrapolated  to  liver  transplant  patients,  the  choice  of  the  anti-
hyperglycemic  agent  should  be  tailored  to  patients’  preference  and  clinical
characteristics[43].  Lifestyle changes represent the first line treatment for glycemic
control,  starting  with  a  balanced diet  low in  calories  and simple  carbohydrates
accompanied by moderate exercise, although this is often difficult in this patient
population with general  frailty persisting many years post-liver transplantation.
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When these measures are not sufficiently effective, pharmacological therapy with
hypoglycemic agents and/or insulin needs to be considered. As the majority of oral
diabetic medications are metabolized in the liver, they should be used with caution in
patients  in  whom  graft  function  is  reduced[44].  Rosiglitazone,  pioglitazone  and
sulfonylureas have been studied in the post-transplant population showing a possible
minimization in insulin requirement[45,46]. Pioglitazone might also be considered in
patients  at  risk  of  developing  de  novo  or  recurrent  NAFLD  after  liver  tr-
ansplantation[47].  Metformin  has  not  been  extensively  studied  in  the  post-liver
transplant setting despite its common use as the first-line therapy choice in type 2
diabetes. A single retrospective analysis of 24 renal transplant recipients treated with
metformin  reported  a  high  rate  of  drug  discontinuation  due  to  gastrointestinal
complaints or an increase in serum creatinine. However, no serious adverse events or
severe alteration in immunosuppression drug levels were recorded[48]. Interestingly, in
vitro analysis revealed that metformin optimally reverts diabetogenic genes that are
dysregulated in the context of immunosuppression, which is something to take into
account  when evaluating  the  choice  of  therapy[49].  More  recently,  glucagon-like
peptide-1 receptor agonist (GLP-1 RAs, i.e., liraglutide) and inhibitors of dipeptidyl
peptidase 4 (DPP-4I or gliptins) were introduced as part of the current antidiabetic
therapy. According to recent guidelines, GLP-1 RAs are recommended in the presence
of established atherosclerotic cardiovascular disease and might be considered for their
additive weight-loss properties. In this scenario, DPP-4I may also be useful because
they  do  not  affect  body  weight[50].  Sitagliptin  or  vildagliptin  use  after  liver
transplantation are not thought to have any significant effect on calcineurin inhibitor
or mTOR inhibitor availability. A possible exception includes use of sitagliptin and
cyclosporine as well as tacrolimus and vildagliptin, drug combinations that warrants
further investigation[51,52]. Finally, there is next to no experience with sodium-glucose
cotransporter  type  2  (SGLT-2)  inhibitors  (i.e.,  canagliflozin,  dapagliflozin  and
empagliflozin)  in  the  setting  of  liver  transplantation.  All  these  drugs  work  by
increasing urinary glucose excretion and are considered highly safe. Nevertheless, we
have to  consider  that  SGLT-2 inhibitors  are  associated with an increased risk of
genital and urinary (the latter only for high doses of dapagliflozin) tract infections[53],
leading to some controversy in a possible use in liver transplant patients. Moreover,
drug  elimination  mainly  occurs  through  hepatic  and  biliary  excretion,  making
difficult the use of this medication when liver enzymes alterations are present[50]. The
use of SGLT-2 inhibitors may have a positive effect in the setting of heart failure or
renal  impairment,  with  a  specific  dose  adjustment  needed  according  to  renal
function[50].  However, the only direct assessment of the potential interaction with
immunosuppressive  drugs  to  date  was  described  in  a  study  including  healthy
volunteers. Co-administration of cyclosporine resulted in a 23% increase in the mean
canagliflozin area under the operating curve (AUC)[54]. The same mechanisms may
result  in  an  increased  exposure  to  calcineurin  inhibitors  and  mTOR  inhibitors,
although further studies are warranted to clarify this possible interaction. In addition,
as impaired insulin secretion is a major determinant for liver transplantation, when
hepatogenous diabetes[55,56] is suspected, drugs capable to improve β-cell function such
as incretins or SGLT-2 inhibitors might be considered.
If  therapeutic  goals  are  not  met  with  lifestyle  changes  and  oral  anti-diabetic
medication, or if the patient becomes metabolically decompensated (symptomatic
hyperglycemia with ketosis), insulin must be administered[57]. Ideally, glucagon-like
peptide-1 receptor agonists should be used, in combination with basal insulin, in
order to reduce the insulin requirement.
In summary, in addition to pharmacological treatment of diabetes mellitus, the
adjustment of immunosuppressive regimens can aid in reducing the risk of post-liver
transplantation diabetes and improve glycemic control. The possible strategy to adopt
consists in minimizing the use of corticosteroids or adopting cyclosporine rather than
the more diabetogenic tacrolimus, as well as titrating tacrolimus by adding other
immunosuppressive agents (i.e., mycophenolate mofetil or mTOR inhibitors). These
possible combinations may help improve glycemic control[57]. Careful attention also
needs to be taken into account with regard to other cofactors, such as the occurrence
of graft rejection, the concomitant presence of renal failure, etc.  As mentioned, all
immunosuppressive  regimen  adjustments  should  be  combined  with  lifestyle
modifications, and a carefully selected antidiabetic therapy (Figure 1).
OBESITY
Obesity is defined by the World Health Organization as a body mass index (BMI) > 30
kg/m2 and morbid obesity as a BMI of > 35 kg/m2[58]. In the past decade, obesity as a
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Figure 1
Figure 1  Proposal of a treatment algorithm for diabetes mellitus type II in liver transplant recipients. GLP-1 RA: Glucagon-like peptide-1 receptor agonist;
SGLT2 inhibitors: Sodium-glucose cotransporter type 2; DPP-4l: Inhibitors of dipeptidyl peptidase 4; NASH: Non-alcoholic steatohepatitis; NAFLD: Non-alcoholic fatty
liver disease.
whole has progressively become a worldwide epidemic and a relevant comorbidity in
the pre-liver transplant setting, with an overt adverse impact on the post-transplant
outcome.  Although  dry  weight  is  not  always  measurable  in  patients  with
decompensated cirrhosis, it is estimated that 15% to 30% of pre-transplant patients
meet the criteria for obesity[59]. Following liver transplantation, weight gain tends to
increase progressively over time. At one-year post-surgery, 33.7% of patients meet
criteria for obesity, and by 5 years, 40.3% of patients are obese[60]. It is frequent that
patients with a history of obesity prior to liver transplantation maintain this tendency
after the surgical intervention. But additionally, one-third of patients with normal
weight prior to transplantation become obese following the procedure[59]. Weight gain
in  the  early  post-transplantation  period is  related  to  several  factors,  such  as  an
increased appetite as a result of the resolution of cirrhosis and thus, absence of a
catabolic  state,  and  the  orexigenic  effect  of  steroids.  Risk  factors  for  post-liver
transplantation obesity include age greater than 50 years, obesity or type 2 diabetes
prior to transplant and NASH as indication to liver transplantation[61]. Patients should
be advised to achieve a healthy body weight prior to liver transplantation, as obesity
is associated with numerous negative postoperative outcomes such as development of
fatty  deposits  in  the  graft,  development  of  diabetes,  higher  cardiovascular  and
oncogenic risk. Furthermore, patients should be made aware of the tendency to gain
weight after transplantation and the problems associated herewith in order to adopt
early preventive measures. Modulating immune suppression, such as adopting a
regimen with a rapid withdrawal of  steroids,  is  one of  the possible  strategies  in
patients at risk. However, it should be noted that steroids are needed not only in the
early  post-liver  transplantation  period,  but  also  in  the  long-term  follow-up  as
treatment of severe cellular rejection, where its use outweighs its associated risks.
While corticosteroids are a well-known cause of weight increase, the effect of the
exposure to the other available immunosuppressant drugs is not completely defined.
Compared with tacrolimus, cyclosporine is associated with more weight gain in the
first year following transplantation, whereas this difference is mitigated 2 years post-
liver transplantation[60]. Recently, in a randomized trial by Charlton et al[62], the authors
found that an early introduction of everolimus with reduced-exposure to tacrolimus
at 1 month post liver transplantation reduced weight gain assessed at 1 and 2 years
post-liver  transplantation.  When  this  reduced-exposure  to  tacrolimus  arm  was
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compared with the absent-exposure to tacrolimus arm, the weight gain was even
lower, suggesting a beneficial effect of isolated everolimus therapy. In addition to
selecting the best immunosuppression therapy, the fundamental approach to treat
and prevent weight gain are lifestyle modifications. Supervised physical activity is
considered safe and effective in stable liver transplant recipients[63]. It is proven that
increasing aerobic capacity and muscle strength has a favorable impact on glucose
homeostasis[64]. There are studies that describe a modified behavior in food intake
before and after liver transplantation, with a positive energy balance in the first year
after  the  surgery[65].  Therefore,  ongoing physical  exercise  and the  adoption  of  a
healthy low-calorie diet  are essential  for the management of  obesity in the post-
transplant setting. Similar to the goals in the pre-transplant setting, the objectives of
treating obesity after liver transplantation are to prevent obesity-related comorbidities
and mortality, as well as to reduce the incidence of de novo NAFLD. When diet and
exercise fail to achieve the proposed goal, pharmacologic therapies and/or bariatric
surgery should be considered. Orlistat was tested in the post-liver transplant setting
and was considered well-tolerated,  safe,  with no need for a close supervision of
immunosuppressant drug levels,  and dietary adherence.  However,  there was no
significant evidence regarding its efficacy[66]. Liraglutide was recently approved for
the treatment of obesity in non-diabetic patients[67], but to date there is no experience
available in liver transplant recipients. Bariatric surgery is considered feasible, when
indicated, although some issues remain. Potential problems include the presence of
extensive adhesions, rendering surgery technically difficult, as well as the increased
risk  of  wound  complications  in  the  setting  of  steroids  or  mTOR  inhibitors[68].
Whenever possible, steroids should be tapered and stopped and mTOR inhibitors
switched to other immunosuppressive agents to reduce the risks of wound healing
problems. In the published literature, only case series are available describing the
implementation of this therapy in liver transplant recipients (Table 1). Despite weight
loss being observed in all reported series (range 21%-75%), high complication rates
(30-40% of complications > grade III of the classification of Clavien-Dindo)[69] were
documented  for  all  types  of  procedures,  particularly  for  sleeve  gastrectomy[70].
Regarding mortality, there were no reports for sleeve gastrectomy, whereas gastric
by-pass  showed  a  mortality  rate  of  20%[71].  Regarding  the  pharmacokinetic  of
immunosuppressant drugs, studies have shown that the kinetics of tacrolimus and
mycophenolate  mofetil  was  not  impacted  by  the  performance  of  a  sleeve
gastrectomy[72]. On the other hand, patients with a gastric by-pass had significantly
modified immunosuppressive drugs serum levels[73].  With currently limited data
available on the effect of both bariatric surgery and pharmacological treatment on
major outcomes such as survival in the post-liver transplant setting, diet and exercise
are still  considered the cornerstone treatment option for tackling and preventing
weight gain.
DYSLIPIDEMIA
High blood lipid levels are unusual in the pre-liver transplant population, due to the
impaired hepatic synthetic function in end-stage liver disease. On the other hand,
dyslipidemia is  a  very common finding in  the  post-liver  transplant  setting.  The
definition of hyperlipidemia varies widely among different studies in the post-liver
transplant era and only a few consider the standard NCEP-ATP III criteria. In view of
this lack of standardization, dyslipidemia is reported as present in 45% to 71% of liver
transplant recipients[74].  In most cases, hypertriglyceridemia occurs in the first six
months after transplantation, maintaining its prevalence throughout the first year,
while it decreases in subsequent years. On the other hand, hypercholesterolemia and
low levels of high-density lipoprotein concentration appear later, with an increasing
prevalence that affects about 30% of patients at the end of the first post-transplant
year[74].
Dyslipidemia  has  multiple  causes  after  liver  transplantation  that  have  been
previously discussed in this review: Frequent body weight increase, poor glycemic
control, genetic predisposition, donor related factors, early post-liver transplantation
renal dysfunction[75] and the effect of immunosuppressant medication[76]. With regard
to  the  latter,  long-term  corticosteroid  use  can  contribute  to  hyperlipidemia[77].
Cyclosporine is more frequently associated with hyperlipidemia (14% vs  5%) and
hypertriglyceridemia  (49% vs  17%)  when compared to  tacrolimus,  with  a  dose-
dependent relationship[78].  The possible explanation for this cyclosporine effect is
related to the inhibition of bile salt synthesis. In the case of tacrolimus, since this drug
is  known  to  cause  hyperinsulinemia,  this  effect  theoretically  may  lead  to  the
development of hypertriglyceridemia. mTOR inhibitors are also known to increase
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Table 1  Series reporting bariatric surgery after liver transplantation
Ref. Year Number ofpatients
Follow-up,
mean (range)
Type of
bariatric
surgery
Improvement of
comorbidities
Complications,
n (%) Mortality, n
Duchini et al[119],
United States
2001 2 27 (18-36) RYGB Yes 0 0
Tichansky et
al[120], United
States
2005 1 4 RYGB Yes 0 0
Butte et al[121],
Chile
2007 1 6 SG NE 0 0
Gentileschi et
al[122], Italy
2009 1 9 BPD NE 0 1 (myocardial
infarction)
Elli et al[123],
United States
2013 1 3 SG NE 0 0
Lin et al[124],
United States
2013 9 5 (3-12) SG Yes 3 (33.3) (1
incisional hernia,
1 bile leakage, 1
dysphagia)
0
Al-Nowayalati et
al[71], United
States
2013 7 59 (6-103) RYGB Yes 4 (57.1) (2
incisional hernia,
2 wound
infections)
2 (1 septic shock
at 6 mo after, 1
esophageal
carcinoma at 9 mo
after)
Pajecki et al[125],
Brazil
2014 1 5 SG Yes 0 0
Elli et al[126],
United States
2016 2 2 SG NE 0 0
Khoraki et al[127],
United States
2016 5 33.7 (13-79) SG Yes 1 (20)
(gastrointestinal
bleeding)
0
Osseis et al[128],
France
2017 6 41 (12-94.4) SG Yes 2 (33.3) (1 gastric
fistula, 1 parietal
mesh infection)
1 (multi-organ
failure at 19 mo
after)
Tsamalaidze et
al[129], Mexico
2018 12 24 SG Yes 4 (33.3) (2
dysphagia, 1 late
drainage removal,
1 gastrostomy)
0
RYGB: Roux-en-Y gastric bypass; SG: Sleeve gastrectomy; BPD: Biliopancreatic diversion; NE: No effect.
the risk of hyperlipidemia (especially hypertriglyceridemia),  through changes in
insulin signaling pathways resulting in an excess of triglycerides production and
secretion[79]. The combination therapy of mTOR inhibitors and tacrolimus results in
lower  rates  of  dyslipidemia[80],  something  also  observed  when  switching  from
cyclosporine to tacrolimus[81]. Post-transplant dyslipidemia is generally resistant to
dietary interventions, but it responds to traditional lipid-lowering agents. The most
recent guidelines of the European Society of Cardiology[82] recommended the use of
low-density lipoprotein concentrations (LDL-C) as the primary target for treatment of
dyslipidemia, while for patients with elevated triglycerides, HDL-C is recommended
as a secondary goal. In primary and secondary prevention for patients catalogued as
having very-high risk for cardiovascular events, an LDL-C reduction of ≥ 50% from
baseline  and  an  LDL-C goal  of  <  1.4  mmol/L (<  55  mg/dL)  are  recommended,
whereas in patients at high risk an LDL-C goal of < 1.8 mmol/L (< 70 mg/dL) is
sufficient.  This  last  version  of  the  European  Society  of  Cardiology  guidelines
dedicated  a  specific  session  on  the  management  of  dyslipidemia  in  solid  organ
recipients, although the recommendations are mostly based on studies on kidney
recipients.  They  conclude  that  the  management  of  dyslipidemia  in  transplant
recipients should be comparable to that recommended for high or very-high risk
patients, with an additional caution for possible drug-drug interactions (Figure 2).
Statins are unanimously considered as a first line therapy for dyslipidemia in liver
transplant patients,  preferably pravastatin and fluvastatin because of  the lack of
interaction  with  cytochrome  P450  and  calcineurin  inhibitors  metabolization[21].
Generally, cyclosporine increases the blood levels of all statins, even more so than
tacrolimus. Nevertheless, statins, with particular reference to pravastatin, have been
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established  to  be  safe,  efficacious  and  well  tolerated  in  solid  organ  transplant
recipients[83].  The concomitant use of other drugs metabolized by the cytochrome
CYP3A4 should be carefully used in patients receiving both calcineurin inhibitors and
statins[82],  because a perturbation in the cytochrome P450 metabolic pathway can
increase  immunosuppressive  drugs  toxicity[84].  Ezetimibe  may  be  considered  in
recipients who do not tolerate statins, although the experience is scant[85]. Concomitant
use of calcineurin inhibitors may result in increased statin levels in the blood. Isolated
hypertriglyceridemia can also be present post- liver transplantation and it generally
responds  well  to  fish  oil.  Omega  3  has  less  drug-drug  interactions  with  im-
munosuppressive therapy. In addition, omega 3 oil has other pleiotropic effects, such
as anti-inflammatory and anti-proliferative properties, which can improve hepatic
steatosis[86]. With regard to other lipid-lowering drugs, such as fibric acid derivatives,
they are usually well tolerated, although there is scarce data available on their use in
liver transplant patients. Importantly, the combination of fibrates with statin therapy
increases the risk of myopathies and is thus not recommended. Patients on both these
medications should be counseled regarding myalgia as a potential early symptom of
rhabdomyolysis[87].
ARTERIAL HYPERTENSION
Arterial hypertension, which is defined as a systolic blood pressure greater than 140
mmHg and/or a diastolic blood pressure greater than 90 mmHg[88], occurs in 30%-50%
of patients after liver transplantation, increasing up to 70% when evaluating patients
in the long term[89,90].  Features such as high cardiac output, low systemic vascular
resistance and low mean arterial pressure characterize end-stage liver disease. After
patients are transplanted, this hemodynamic situation changes, leading to an increase
in systemic blood pressure. Nevertheless, the etiology of post-liver transplantation
hypertension is multifactorial and includes not only this change in hemodynamics,
but also the use of immunosuppressive medications. These drugs are a well-known
risk factor for hypertension, in particular calcineurin inhibitors. Although there are
numerous pathogenetic mechanisms related to the development of hypertension in
such patients, vasoconstriction seems to be the main causal factor. Vasoconstriction is
caused by the excessive secretion of endothelin-1 and thromboxane and decreased
production of prostacyclin, leading to an increase in sympathetic nervous system
activity. In addition to these mechanisms, cyclosporine and tacrolimus act on sodium
retention, resulting in an increase in effective-volume[90]. Nevertheless, cyclosporine
seems to have a more deleterious effect compared to tacrolimus, showing a higher
prevalence  rate  of  arterial  hypertension  (73%  vs  63%,  respectively) [91].  Glu-
cocorticosteroids  are  also  a  known  cofactor  for  the  development  of  arterial
hypertension.  They  increase  blood  pressure  through  the  renin-angiotensin-
aldosterone system, causing a reduction in prostacyclin and nitric oxide production,
and an increase in the quantity of angiotensin II receptors[92]. However, considering
the usually short time of exposure to steroids in these patients, calcineurin inhibitors
are  the  main  agent  responsible  for  the  long-term  development  of  arterial
hypertension. The main concern about arterial hypertension is related to the direct
damage on organs and its established association to increased risk for cardiovascular
events[93]. Elevated blood pressure may lead to endothelial damage, atherosclerosis,
kidney damage and left ventricle remodeling. Hypertensive control is essential to the
improvement of long-term survival of both the graft and the recipient, related to the
non-negligible risk of developing major cardiovascular events. The withdrawal of
steroid  therapy,  the  down-titration  of  calcineurin  inhibitors  (when  adding
mycophenolate mofetil  or mTOR inhibitors) are possible strategies to reduce the
increase  in  blood pressure  values.  Lifestyle  modifications  (i.e.,  low-sodium diet,
cessation of smoking, avoidance of alcohol, and weight loss) should always be clearly
explained  to  the  patient.  Nevertheless,  when  these  measures  are  unsuccessful,
medical  therapy is  mandatory.  A blood pressure goal  lower than 130/80 mmHg
should be targeted to  minimize cardiovascular  risk[94].  Dihydropyridine calcium
channel blockers are the preferred first-line agents in patients who do not exhibit
proteinuria,  in  order  to  directly  counteract  the  vasoconstriction associated with
calcineurin inhibitors[95]. If proteinuria is present, liver transplant recipients benefit
from angiotensin-converting enzyme (ACE) inhibitors  or  angiotensin II  receptor
blockers as a first line choice[95]. If a single-agent therapy is ineffective, a combination
therapy should be evaluated, taking into account that the addition of beta-blockers is
particularly indicated when a cardiac complication is well established[96]. Furthermore,
angiotensin-converting enzyme inhibitors and angiotensin-2 blockers may magnify
the collateral effects of calcineurin inhibitors such as hyperkalemia and metabolic
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Figure 2
Figure 2  Proposal of a treatment algorithm for low-density lipoprotein cholesterol lowering strategy in liver
transplant recipients.1Class of recommendation: IIa; level of evidence: B, according to 2019 ESC/EAS Guidelines
for the management of dyslipidaemias[118]. 2Class of recommendation: IIb; level of evidence: C, according to 2019
ESC/EAS Guidelines for the management of dyslipidaemias[118]. LDL-C: Low-density lipoprotein cholesterol.
acidosis, so it is advisable to use them during the long-term follow-up after liver
transplantation, when the activation of the renin-angiotensin system becomes more
evident. Diuretic therapy is typically avoided, due to the fact that volume contraction
in  the  face  of  renal  vasoconstriction  may  lead  to  further  impairment  in  renal
function[97].
It is important to keep in mind that drug-drug interactions are frequent in this
subgroup of patients. Certain antihypertensive medications, namely beta-blockers,
can significantly impact levels of immunosuppressive medication, thus they should
be monitored during the introduction of  any new drug.  Independently from the
chosen approach for blood pressure control, the end goal is to find a balance between
antihypertensive therapy and immunosuppressive therapy modulation.
RENAL IMPAIRMENT
One of the most frequent medium- and long-term medical complications after liver
transplantation is the development of nephrotoxicity, which is estimated to be 8%,
13.9% and 18.1% at 12, 36 and 60 mo post-transplant respectively[98]. Major causes of
renal injury include the diagnosis of renal failure and/or hepatorenal syndrome prior
to  liver  transplantation,  critical  intraoperative  variables  such  as  the  need  for
vasopressors[99], donor-related variables such as donation after circulatory death, cold
ischemia time, and graft  steatosis[100,101].  All  of these features are well  established
predictors of renal insufficiency after liver transplantation, particularly in the early
post-surgical  phase.  However,  in  the  majority  of  the  cases,  renal  impairment  is
strongly associated with the direct side effects of immunosuppressive drugs in a dose
dependent manner, such as calcineurin inhibitors. Nevertheless, it can also occur with
combination regimens that aim to achieve low serum levels of tacrolimus. These
findings have suggested the existence of different types of kidney damage based on
different,  partially reversible,  mechanisms. The first type of damage is early and
reversible, characterized by vasoconstriction of the kidney afferent arteriole, with a
consensual reduction in glomerular filtration rate. A second and often irreversible
damage  is  characterized  by  hyaline  degeneration  of  renal  arterioles,  leading  to
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glomerulosclerosis[102]. In this setting, the withdrawal of cyclosporine or tacrolimus is
not  effective  for  the  recovery  of  kidney  damage.  Thus,  early  detection  of  renal
impairment after liver transplantation is essential in order to implement different
strategies  to  reduce  calcineurin  inhibitors  levels.  The  introduction  of  immuno-
suppressive combination therapies such as adding mTOR inhibitors to low doses of
calcineurin inhibitors represents a possibility to minimize the exposure to nephrotoxic
agents,  sparing  kidney  function,  without  an  increase  in  graft  rejection  rates[103].
Recently, new findings regarding the relationship between cardiovascular events after
liver transplantation and renal impairment have been documented, underlying that
even mild renal disease at the time of liver transplantation is a risk factor for post-
transplant all-cause and cardiovascular mortality[104]. In a retrospective study on 202
transplant  candidates  pre-transplant  renal  impairment  was  found  to  be  an
independent predictor of post-transplant cardiac events (HR = 2.19, 95%CI: 1.25-3.85)
and reduced cardiac event-free survival (HR = 2.27, 95%CI: 1.31-3.94)[105]. In addition,
the  velocity  of  the  decline  of  glomerular  filtrate  rate  after  liver  transplantation
strongly correlated with the risk of adverse cardiovascular outcomes, highlighting the
need to preserve early renal function in order to reduce these complications[104].
CARDIOVASCULAR DISEASES
Cardiovascular diseases affect long-term prognosis after solid organ transplantation.
Nevertheless,  this  risk  is  substantially  different  for  liver  transplant  recipients
compared to other solid organ recipients. This is partially related to hemodynamic
and  metabolic  changes  associated  with  chronic  liver  disease[106].  The  marked
peripheral vasodilatation present in patients with decompensated end-stage cirrhosis
makes  difficult  the  detection  of  a  latent  myocardial  dysfunction  with  cardiac
abnormalities, such as an attenuation in the systolic and diastolic contractile responses
leading to the so-called cirrhotic cardiomyopathy. These changes, combined with
reduced serum cholesterol, can mask pre-liver transplant cardiovascular risk factors,
increasing the challenge to identify those patients at highest risk for cardiovascular
diseases [97].  The  relevance  is  notable  when  analyzing  mortality  after  liver
transplantation:  It  is  estimated  that  12%-16%  of  deaths  one  year  after  liver
transplantation in the USA is due to cardiovascular disease[7]. In Europe, the median
estimated 10-year risk of fatal cardiovascular disease is 1% (range: 0%-9%) and 10% of
the affected patients have a high risk for these events[107]. A detailed cardiovascular
assessment during pre-liver transplant evaluation is  thus mandatory to not only
assess the perioperative risk but also to allow for an early intervention, if needed, to
ensure a good long-term outcome. Despite no guidelines being available in the pre-
liver transplant assessment for cardiovascular disease, every transplant center adopts
different routines for cardiovascular assessment, in order to stratify the population
risk.
Standard evaluation before liver transplantation normally includes a full history
and  clinical  examination,  peripheral  artery  oxygen  saturation,  12  lead
electrocardiogram and a complete transthoracic ultrasound with assessment of left
ventricular, right ventricular and valvular function (with an estimation of systolic
pulmonary artery pressure). Further investigations, such as stress echocardiography,
cardiac computerized tomographic scan, cardiac magnetic resonance or angiography
are solicited based on medical history, cardiology indication and findings from the
initial screening tests[108]. It should be noted that second line tests such as dobutamine
stress echocardiography have shown a poor predictive value for coronary artery
disease screening (sensitivity: 28%), although with high specificity (specificity: 82%),
compared with the gold standard coronary angiography[109]. When using a protocol
angiography  in  the  pre-transplant  cardiac  evaluation,  36%  of  patients  showed
coronary artery disease in a recently published study, with NASH and hepatitis C
being independent risk factors[110]. However, another study showed that the incidence
of major cardiovascular events and overall survival after liver transplantation are
similar between patients with and without coronary evaluation[111]. In another study
where a control group without cardiovascular risk factors was matched with a group
with coronary artery disease showed that the severity or extent of coronary artery
disease  does  not  affect  post  liver  transplantation  survival,  if  appropriately  re-
vascularized. However, early postoperative cardiac events could be associated with
lower survival rate, irrespectively of underlying coronary artery disease[112]. Hence, it
is unclear how many pre-liver transplant asymptomatic cardiovascular abnormalities
could influence long-term outcome after transplantation. On the other hand, it seems
that cardiac complications are significantly more frequent in patients with a pre-liver
transplant  known  heart  disease  compared  with  those  without  pre-existing
WJG https://www.wjgnet.com May 14, 2020 Volume 26 Issue 18
Becchetti C et al. Metabolic complications after liver transplantation
2148
cardiovascular  disease[113].  Since  liver  transplantation  is  a  significantly  stressful
procedure from a cardiovascular standpoint, cardiovascular mortality is of the utmost
importance,  particularly  when  cirrhotic  cardiomyopathy  is  unknown  or  un-
derestimated[114]. Following liver transplantation, peripheral vascular resistance and
blood pressure rapidly increase; these changes may cause an overt cardiac failure
leading to pulmonary edema in predisposed patients. Other possible cardiovascular
complications include the development of post-operative atrial fibrillation, defined as
a new-onset atrial fibrillation during liver transplantation surgery or within 30 d after
this procedure in a patient without previous episodes. This phenomenon can drive to
hemodynamic and thromboembolic events, significantly affecting the prognosis of the
patients in the early post-liver transplantation[115]. Although the impact of these early
events on the long-term cardiovascular prognosis has not been explored in detail, a
recent  retrospective  study  in  over  1000  liver  transplant  patients  found that  the
development of postoperative atrial fibrillation is an independent risk factor for post-
liver transplant mortality (OR = 2.0; 95%CI: 1.3-3.0; P  < 0.01)[116].  Furthermore, as
might be expected, NASH as an indication for liver transplantation had a significantly
higher risk of a cardiovascular event 1 and 3 years after liver transplant. Even with a
relatively low prevalence, major cardiac events are significantly associated with a
lower 5-year survival rate, thus stressing the importance of identifying and stratifying
high-risk patients prior to liver transplantation and offering targeted postoperative
interventions.  A study of  Patel  et  al[117]  has  recently  shown that  despite  that  the
presence and severity of pre-transplantation coronary artery disease may not affect
post transplantation survival, the use of statins in the post-transplantation period
might  confer  a  survival  benefit  (HR = 0.25;  95%CI:  0.12-0.49;  P  <  0.001).  This  is
independent  of  the  use  of  aspirin,  which  did  not  show  an  effect  on  mortality.
Nonetheless, the study highlighted that statin therapy is still very much underused,
with only 46% of patients with proven coronary artery disease benefitting from this
therapy. The medication was well tolerated (only 12% of recipients needed to stop the
therapy due to side effects)[117], suggesting a promising role of statins in improving the
outcomes after liver transplantation.
CONCLUSION
The  proper  identification  of  liver  transplant  recipients  at  risk  of  metabolic  and
cardiovascular morbidity and mortality after liver transplantation is still far from
being satisfactory. Literature devoted to this topic is scarce and often of low quality,
making it difficult to provide recommendations or to develop appropriate guidelines.
Moreover,  the  efficacy  and  safety  of  the  current  treatment  strategies  for  these
metabolic complications needs to be validated in this specific population, as well as
finding adequate surrogates which can be considered suitable targets to impact on the
prognosis of liver transplant recipients.
However, as survival rate after liver transplantation increases, it seems clear that
the management of metabolic complications and cardiovascular disease requires
heightened attention. These comorbidities have a major impact on the morbidity,
mortality and quality of life of liver transplant recipients in the late postoperative
period. Early identification and proper management of these metabolic alterations,
initially acting on lifestyle modifications, immunosuppression titration, and tailored
medical therapy remain crucial to improve the outcome of liver transplant patients.
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